Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Emmanuel S. Buys, Lincoln R. Potter, Louis R. Pasquale, Bruce R. Ksander

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

Glaucoma is a progressive optic neuropathy characterized by visual field defects that ultimately lead to irreversible blindness (Alward, 2000; Anderson et al., 2006). By the year 2020, an estimated 80 million people will have glaucoma, 11 million of which will be bilaterally blind. Primary open-angle glaucoma (POAG) is the most common type of glaucoma. Elevated intraocular pressure (IOP) is currently the only risk factor amenable to treatment. How IOP is regulated and can be modulated remains a topic of active investigation. Available therapies, mostly geared toward lowering IOP, offer incomplete protection, and POAG often goes undetected until irreparable damage has been done, highlighting the need for novel therapeutic approaches, drug targets, and biomarkers (Heijl et al., 2002; Quigley, 2011). In this review, the role of soluble (nitric oxide (NO)-activated) and membrane-bound, natriuretic peptide (NP)-activated guanylate cyclases that generate the secondary signaling molecule cyclic guanosine monophosphate (cGMP) in the regulation of IOP and in the pathophysiology of POAG will be discussed.

Original languageEnglish (US)
Article number38
JournalFrontiers in Molecular Neuroscience
Volume7
Issue numberMAY
DOIs
StatePublished - May 19 2014

    Fingerprint

Keywords

  • Glaucoma
  • Guanylate cyclase
  • Intraocular pressure
  • Natriuretic peptides
  • Nitric oxide
  • Open-angle

Cite this